Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Buildings (2016 - 2023)

Historic Buildings for China Pharma Holdings (CPHI) over the last 15 years, with Q2 2023 value amounting to $9.1 million.

  • China Pharma Holdings' Buildings fell 711.89% to $9.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $9.1 million, marking a year-over-year decrease of 711.89%. This contributed to the annual value of $9.4 million for FY2022, which is 845.56% down from last year.
  • Latest data reveals that China Pharma Holdings reported Buildings of $9.1 million as of Q2 2023, which was down 711.89% from $9.5 million recorded in Q1 2023.
  • China Pharma Holdings' 5-year Buildings high stood at $10.3 million for Q1 2022, and its period low was $9.1 million during Q2 2023.
  • For the 5-year period, China Pharma Holdings' Buildings averaged around $9.7 million, with its median value being $9.6 million (2020).
  • As far as peak fluctuations go, China Pharma Holdings' Buildings surged by 958.81% in 2021, and later crashed by 865.38% in 2022.
  • China Pharma Holdings' Buildings (Quarter) stood at $9.4 million in 2019, then rose by 6.92% to $10.0 million in 2020, then grew by 2.34% to $10.3 million in 2021, then decreased by 8.46% to $9.4 million in 2022, then decreased by 3.61% to $9.1 million in 2023.
  • Its Buildings was $9.1 million in Q2 2023, compared to $9.5 million in Q1 2023 and $9.4 million in Q4 2022.